Niemann-Pick C1-like 1 protein (NPC1L1) plays a critical role in intestinal cholesterol absorption. Our objective was to examine whether 5 variants (-133 A>G, -18A>C, L272L, V1296V, and U3_28650A>G) at the NPC1L1 gene have effects on lipid levels, prevalence and incidence of coronary heart disease (CHD), and lipid-lowering response to pravastatin. We studied 5804 elderly participants from the PROSPER study, who were randomized to pravastatin 40 mg/day or placebo and were followed on average for 3.2 years. In the adjusted gender-pooled analyses, homozygous carriers of the minor alleles at four NPC1L1 sites (-18A>C, L272L, V1296V, and U3_28650A>G, minor allele frequencies 0.15 -0.33) had 2-8% higher low-density lipoprotein (LDL) cholesterol (C) levels at baseline than homozygous carriers of the common alleles (p<0.05).
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INTRODUCTION.
Elevated plasma low-density lipoprotein cholesterol (LDL-C) and reduced highdensity lipoprotein cholesterol levels independently predict risk of developing coronary heart disease (CHD) (1) (2) . Dietary cholesterol consumption and intestinal absorption contribute to plasma cholesterol levels. Markers of intestinal cholesterol absorption, such as beta-sitosterol and campesterol, have been related to variation in levels of plasma LDL-C in human population studies (3) (4) (5) (6) . Niemann-Pick C1-like 1 (NPC1L1) is an essential protein for intestinal cholesterol absorption (7) . NPC1L1 was identified based on its homology to human Niemann-Pick C1 (NPC1) protein, which is defective in an autosomal recessive lipid storage disorder (8, 9) . NPC1L1-deficient mice exhibit a substantial reduction in cholesterol absorption, which is unaffected by dietary supplementation of bile acids (10) . Recent data indicate that hepatic NPC1L1 also facilitates the retention of biliary cholesterol by hepatocytes, thus protecting the body from excessive biliary loss of cholesterol (11) .
Cohen et al. have sequenced NPC1L1 and showed that individuals who carry rare NPC1L1 variants associated with decreased cholesterol absorption have mean LDL-C levels that are significantly lower than values in non-carriers (12) . Moreover, NPC1L1 is the target for the drug ezetimibe, which inhibits cholesterol absorption (13) . Genetic variation at NPC1L1 in humans has been shown to affect LDL-C lowering response to ezetimibe (14) (15) (16) . Simon et al. have assessed a number of single nucleotide polymorphisms (SNPs) at NPC1L1 and reported that carriers of the rare alleles (most significantly the promoter variant at -18A>C) had a 15% greater LDL-C lowering response to ezetimibe as compared to non-carriers (14) . Furthermore, Hegele et al. have shown that individuals with dyslipidemia who carry a rare NPC1L1 haplotype including the minor alleles at L272L, V1296V, and 25342A>C were more responsive to ezetimibe (36% LDL-C reduction) than subjects not carrying the haplotype (18% LDL-C reduction) (16) We and others have documented that alterations in specific plasma markers of cholesterol absorption, namely campesterol and beta-sitosterol, can affect LDL-C lowering response to statins (17) (18) (19) (20) . Moreover, it has been reported that a subset of patients placed on simvastatin in the Scandinavian Simvastatin Survival Study showed no benefit from therapy as compared to placebo if they had elevated baseline levels of markers of cholesterol absorption, including cholestanol (21) . Given the significant role of the NPC1L1 gene in cholesterol absorption and its reported involvement in the by guest, on www.jlr.org Downloaded from 4 pharmacogenetics of ezetimibe and the ezetimibe/statin combination, our goal was to examine potential associations of the SNPs selected on the basis of previously published associations (14) (15) (16) , functional relevance, and minor allele frequencies of >10%, namely, -133A>G, -18A>C, L272L, V1296V and U_28650A>G, with baseline lipid levels, history and incidence of coronary heart disease, and lipid-lowering response to pravastatin in PROSPER (Prospective Study of Pravastatin in the Elderly at Risk).
MATERIALS AND METHODS
Study Subjects: The protocol of the PROSPER study has previously been published (22) , as have the PROSPER results (22) . Briefly, 2804 men and 3000 women, age range 70 to 82 years, with pre-existing vascular disease (n=2404) or at least one of three major vascular risk factors (diabetes n= 575, smoking n= 1433, or hypertension n= 3360) were randomized to pravastatin 40 mg/day (n = 2891) or placebo (n = 2913) and followed-up on average for 3.2 years. Over this period, the mean LDL-C reduction in the active treatment group was 32%, and the risk of developing CHD was decreased by 19% (18) . No significant lipid changes were noted in the placebo group. Lipid levels were similar at onset of the study in subjects randomized to pravastatin or placebo. Analysis of response to pravastatin was based on subjects reporting good compliance (65% of the subjects in the pravastatin group were in this category, with good compliance being defined as taking 90% or more of the medication).
Biochemical and DNA Analysis: Total (T) C, HDL-C, and triglycerides were assessed after an overnight fast, at baseline and at 6 months, and LDL-C was calculated by the Friedewald formula, as previously described (22, 23) . Apolipoprotein (apo) B was measured only at baseline as described (23) . DNA was available from 5783 subjects and isolated from peripheral blood. DNA and subject characteristics were available on 2621 males and 2796 females. ApoE phenotype was determined on plasma samples by western blotting, using the method of Havekes et al (24) in the central laboratory of the Royal Infirmary in Glasgow, Scotland. Subjects were classified according to the presence of apoE2, apoE3, or apoE4 bands on gel blotting.
Five SNPs in the NPC1L1 locus were genotyped in the present study; two in the promoter region (-18 A>C (dbSNP reference number is not available) and -133 A>G (rs17655652), two in the protein coding region, 1679 C>T, or L272L (rs2072183) and by guest, on www.jlr.org Downloaded from 5 27621 T>C, or V1296V (rs217434), and one in the 3' untranslated region (UTR), U3_28650A>G (rs3187907)). The SNPs were selected based on previously published associations (15, 16) , functional relevance, and minor allele frequencies of >10%. We used Taq Man® SNPs genotyping assays (Applied Biosystems, Foster City CA). The Genbank/EMBL accession numbers for NPC1L1 is NC_000007.12, mim 608010. The end point read was performed using an Applied Biosystems 7900 HT Sequence Detection System, subsequent to PCR amplification. Genotypes with quality scores below 95% were repeated and 5% blinded replicates for genotype determinations were performed. In addition, subjects with the apoE4/2 phenotype (n=119; 2.2%) were excluded from further analyses, as were subjects whose apoE phenotypes had not been ascertained (n=246). These exclusions were implemented because apoE phenotype or genotype has been demonstrated to affect statin-induced LDL lowering response, as well as CHD risk (25) (26) (27) (28) (29) , with apoE2 and apoE4 phenotypes having opposite effects. interaction, haplotypes were used as predictors in the regression models instead of SNPs along with the non-genetic covariates. P values were adjusted for multiple comparisons across genotypes within each SNP using the permutation test using 10,000 permutations.
All analyses were performed using SAS/STAT (SAS version 9.1, SAS Institute, Inc., Cary, NC).
RESULTS
As summarized in Table 1 , the participating subjects had a mean age of 75±3 years at baseline. Mean LDL-C levels were in the moderate-risk category (130-160 mg/dl), as defined by the United States National Cholesterol Education Program (31).
Also, 1371 men and 1033 women reported a history of all types of vascular disease, including 508 men and 222 women with a history of MI. Data on apoE phenotype distribution in this population are also shown in Table 1 . Allele frequencies for the NPC1L1 SNPs are given in Figure 1 , along with the haplotype block structure. Genotype frequencies conformed to Hardy-Weinberg equilibrium (p>0.05, data not shown).
Association with Baseline Levels
Baseline lipid and apoB levels stratified by genotype and gender are shown in Table   2 . In the sex-pooled adjusted model, the minor alleles of -18 A>C, L272L, V1296V, and U3_28650A>G were associated with slightly higher TC, LDL-C, and apoB levels in both men and women (differences ranged between 2% and 8% when comparing homozygotes for the minor allele with homozygotes for the common allele; p<0.05).
Significant associations between the -133A>G variant and lipid levels were most pronounced in women, with -133 GG female carriers having the lowest TC and LDL-C levels as compared to -133 AA and -133 AG carriers (p for trend = 0.0032 for TC and 0.023 for LDL-C; Table 2 ). Similar trends were noted in men, but did not reach statistical significance (p for trend= 0.46 for TC and 0.09 for LDL; Table 2 ).
Haplotype analysis detected two LD blocks with two SNPs each and one SNP between the blocks. In order to test allelic interactions and preserve power, we constructed haplotypes that included one SNP from each haplotype block and the SNP outside of either haplotype block (-18 A>C, L272L, and U3_28650A>G) ( Figure 1 and (Table 3) . This is consistent with the data shown in Table   2 where individual variations in these SNPs were significantly associated with LDL-C levels with homozygous carriers for the minor alleles having the highest levels. These data indicate that most of the variation in TC and LDL-C levels could be explained by individual SNPs, and that haplotype analysis did not add significantly to the model performance. The proportion of variation explained by multivariable models with individual SNPs was on average 15.5% for baseline LDL-C levels and 17.4% for baseline TC, while multivariate models with haplotypes explained 15.6% and 17.4%, respectively (p for model comparison >0.05).
Associations with Response to Treatment
To assess differential responsiveness to pravastatin in carriers of various NPC1L1 genotypes, we tested the association between the SNPs under study and the 6-month change in lipid levels in treated individuals with good compliance. The -133 A>G variant was associated with LDL-C lowering in the sex-pooled analysis (p=0.02). However, while -133GG male carriers showed the greatest reduction in LDL-C following pravastatin treatment as compared to carriers of one or two major alleles, -133GG female carriers had the lowest reduction compared to carriers of one or two major alleles (p-value for SNP-sex interaction is 0.006, Figure 2 ). Other SNPs were not related to LDL-C lowering response to pravastatin (see Supplementary Table I) .
Associations with History and Incidence of Cardiovascular Disease
At Table II) .
Hazard ratios (HR) for incident CHD death or non-fatal MI (total number of new cases n= 597) stratified by gender and genotype are shown in Table 4 . All the SNPs that were significantly associated with higher TC, LDL-C and apoB were also found to be (Table 4) . However, statistical significance was achieved only when pravastatin and placebo groups were combined and adjusted for treatment, likely due to reduced statistical power in the stratified analysis (Table 4) .
DISCUSSION
The purpose of the present study was to evaluate associations of SNPs at the NPC1L1 locus with baseline lipid levels, history of vascular disease, incident coronary heart disease, and LDL-C lowering response to pravastatin in a large population of elderly subjects at increased risk of developing CHD. The NPC1L1 transporter has been shown to be critical for cholesterol absorption, and is the site of the action of ezetimibe, a cholesterol lowering agent which inhibits cholesterol absorption (8, 9,13).
In the current study we documented that homozygous carriers of the minor alleles at -18A>C, L272L, V1296V, and U3_28650A>G at the NPC1L1 locus had 2 to 8% higher TC, LDL-C, and apoB levels at baseline as compared to their common allele homozygous counterparts. An opposite trend was observed for NPC1L1 -133 A>G, primarily in women. Additional support for the effect of the NPC1L1 -133 A>G SNP and lipid levels was obtained in a recent meta-analysis of genome-wide association studies involving 8,816 subjects which included controls, diabetics, and myocardial infarction survivors, mainly of European origin (32) . In that study, carriers of the NPC1L1 -133 A>G common allele had higher LDL-C levels (on average 2.4 mg/dl per copy, p=0.018, not significant at the genome-wide level) (32) . Neither L272L nor V1296V or U3_28650A>G
were found to be associated with cross-sectional lipid levels assessed in this metaanalysis (32). It is possible that population characteristics, such as the cardiovascular risk profile, age, and prior history of CHD, as well as differences in covariates controlled for by our studies, can, at least in part, explain these latter differences.
Analyses of associations between genotypes and response to pravastatin were prompted by reports that NPC1L1 variants were related to LDL-C lowering response to ezetimibe (14-16). We found that the NPC1L1 -133 A>G SNP, but not other NPC1L1
SNPs, was associated with response to pravastatin. Simon et al. (15) have reported that NPC1L1 -133 GG carriers had a poorer LDL-C lowering response to statin-ezetimibe combinations as compared to NPC1L1 -133 AA carriers, similar to our finding with pravastatin therapy alone. In our study, these differences were only observed in women. Moreover, female homozygotes for -133AA
had significantly greater reductions than their male counterparts, while the converse was true for females carrying -133GG (see Figure 2) . It should however be noted that the former group had lower LDL-C levels at baseline, which, unless the effect of pravastatin is scale-independent, could have accounted for some of these results. Moreover, although we cannot rule out a spurious association, we speculate that this phenomenon can also be explained by differences in binding affinity of transcription factors and their ligands, such as estrogen receptors, whose activity may differ between men and women.
We have previously documented that genetic variation at the estrogen receptor alpha gene locus is associated with gender specific differences in LDL-C lowering response to atorvastatin (33) . While our data suggest sex-specific effects of the NPC1L1 genotype A novel feature of our study is that we ascertained whether there was an association of NPC1L1 polymorphisms and vascular disease. More than half of the men and more than a third of the women participating in PROSPER had a prior history of cardiovascular events. However, none of the SNPs were associated with a history of vascular disease at baseline. Of note is that the allele frequencies for the NPC1L1 SNPs that we observed in PROSPER were similar to those reported by other studies (15, 16) and conformed to those expected by Hardy-Weinberg equilibrium. Therefore, no survival bias with regard to these variants was implied. However, the rare alleles -18A>C, L272L, V1296V, and U3_28650A>G at NPC1L1 were associated with a 50%-67% increased risk of developing fatal or non-fatal CHD events on trial. Moreover, the higher incidence of new CHD death or non-fatal MI in carriers of minor alleles did not appear to be modified by statin treatment, indicating that pravastatin is not effective in CHD risk reduction in this subgroup of patients. These subjects may be similar to those previously identified by Miettinen et al. that had higher baseline markers of cholesterol absorption and had no significant CHD risk reduction despite simvastatin treatment as compared to placebo in the 4S study (21) .
It is important to note that the design of this study does not allow us to draw definitive conclusions about the exact mechanisms that may lead to genotype-related differences there is accumulating evidence suggesting that synonymous changes introduce rare codons, which may result in altered translation rates and protein folding. (34, 35) . In addition, the SNP in the untranslated region could be associated with alterations in the post-transcriptional regulation that might affect NPC1L1 gene expression. The next step would be to sequence the genomic region at and near NPC1L1 and search for functional, and as yet unknown, variants that can explain the associations detected in this study.
The limitations of our study include the fact that our cohort is elderly and of European origin, restricting generalizibility of our findings to those of younger individuals and those of other ethnic backgrounds. However, the consistency and biological relevance of these associations should motivate further research to verify and extend these findings and test their relationship with specific markers of intestinal cholesterol absorption, such as beta-sitosterol and campesterol (17) .
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In summary, our data are consistent with the hypothesis that genetic variation at NPC1L1 is associated with plasma total cholesterol and LDL-C levels and CHD risk due to alterations in cholesterol absorption in an elderly European population. In the future, re-sequencing of NPC1L1 and precise elucidation of the effects of NPC1L1 variants on NPC1L1 gene expression and function should improve our understanding of how genetic variation at this gene affects lipid concentrations, CHD risk, and response to lipidlowering treatments.
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